Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Zevra Therapeutics (ZVRA) Equity Average: 2015-2025

Historic Equity Average for Zevra Therapeutics (ZVRA) over the last 10 years, with Sep 2025 value amounting to $125.2 million.

  • Zevra Therapeutics' Equity Average rose 144.89% to $125.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $125.2 million, marking a year-over-year increase of 144.89%. This contributed to the annual value of $50.8 million for FY2024, which is 25.88% down from last year.
  • Per Zevra Therapeutics' latest filing, its Equity Average stood at $125.2 million for Q3 2025, which was up 58.22% from $79.1 million recorded in Q2 2025.
  • Zevra Therapeutics' 5-year Equity Average high stood at $438.4 million for Q2 2023, and its period low was $8.9 million during Q1 2021.
  • In the last 3 years, Zevra Therapeutics' Equity Average had a median value of $61.7 million in 2023 and averaged $132.1 million.
  • Per our database at Business Quant, Zevra Therapeutics' Equity Average surged by 3,036.46% in 2022 and then tumbled by 90.73% in 2024.
  • Over the past 5 years, Zevra Therapeutics' Equity Average (Quarterly) stood at $129.4 million in 2021, then spiked by 97.12% to $255.1 million in 2022, then tumbled by 75.82% to $61.7 million in 2023, then dropped by 11.31% to $54.7 million in 2024, then spiked by 144.89% to $125.2 million in 2025.
  • Its last three reported values are $125.2 million in Q3 2025, $79.1 million for Q2 2025, and $40.3 million during Q1 2025.